Key Highlights
- Cue Biopharma shares ended the day down 19% at $27.64.
- The company disclosed a widened Q2 net loss of $153.1 million.
- The loss was heavily impacted by CUE-221 licensing fees and non-cash Acquisition costs.
- A Boehringer Ingelheim milestone boosted quarterly Revenue to $7.9 million.
Cue Biopharma, Inc. (NASDAQ: CUE) shares ended the day down 19% at $27.64 after the company disclosed a widened Q2 net loss of $153.1 million, a figure heavily impacted by CUE-221 licensing fees and non-cash acquisition costs.
What Happened
Even as a Boehringer Ingelheim milestone boosted quarterly revenue to $7.9 million, the market now anticipates Phase 2 data for CUE-221 in CSU by the close of Q3 2026, alongside a projected IND submission and Phase 1 start for CUE-401 later this year.
Market Reaction
Shares fell sharply as investors focused on the scale of the widened net loss, despite the offsetting boost to revenue from the Boehringer Ingelheim milestone payment.
Outlook
Phase 2 data for CUE-221 in chronic spontaneous urticaria, expected by the close of the third quarter of 2026, along with the projected IND submission and Phase 1 start for CUE-401 later this year, represent the next major disclosed milestones for Cue Biopharma.
FAQs
Q: Why did Cue Biopharma shares fall 19%?
A: Shares fell after the company disclosed a widened Q2 net loss of $153.1 million, driven by CUE-221 licensing fees and non-cash acquisition costs.
Q: What boosted Cue Biopharma's quarterly revenue?
A: A milestone payment from Boehringer Ingelheim, which boosted revenue to $7.9 million.
Q: What upcoming catalysts is the market watching?
A: Phase 2 data for CUE-221 in CSU by the end of Q3 2026, and a projected IND submission and Phase 1 start for CUE-401 later this year.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.